文献速递艾滋病与性传播感染

整合酶抑制剂与蛋白酶抑制剂方案治疗晚期HIV疾病的LAPTOP随机试验

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.
PubMed 文献 · Lancet Infect Dis · 2025-12-01

LAPTOP是一项多国、随机、开放标签、非劣效性试验,纳入治疗初治的晚期HIV疾病成人,比较比克替拉韦联合方案与达芦那韦/考比司他联合方案治疗48周的效果。结果显示整合酶抑制剂组主要复合终点事件少于含增效蛋白酶抑制剂组,非劣效性成立,且药物相关不良事件更少。

要点

  • 比克替拉韦方案在晚期HIV疾病中非劣效于达芦那韦/考比司他方案
  • 整合酶抑制剂组48周主要复合终点事件比例低于含增效蛋白酶抑制剂组
  • 整合酶抑制剂组药物相关不良事件(≥2级)更少

核心结论

  • 在晚期HIV疾病治疗初治成人中,比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺非劣效于达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺,且不良事件更少,支持其作为该人群首选一线方案。

研究设计与样本

  • 多国、随机、开放标签、非劣效性试验,在西班牙、法国、意大利、德国、比利时、爱尔兰和英国7个欧洲国家开展。
  • 治疗初治的晚期HIV疾病成人按1:1随机分配至整合酶抑制剂组(比克替拉韦+恩曲他滨+替诺福韦艾拉酚胺)或含增效蛋白酶抑制剂组(达芦那韦+考比司他+恩曲他滨+替诺福韦艾拉酚胺),疗程48周。
  • 2019年5月13日至2023年6月26日共随机分配222例至整合酶抑制剂组、225例至含增效蛋白酶抑制剂组;447例中442例(99%)接受至少一剂,中位CD4计数41 cells/μL(IQR 17-79)。
  • 主要复合终点采用Kaplan-Meier和Cox回归在改良意向治疗(mITT)和符合方案人群中评估;95% CI的HR上限小于1·606即判定非劣效。

主要发现

  • mITT分析中,48周主要复合终点事件在整合酶抑制剂组220例中发生49例(22%),含增效蛋白酶抑制剂组222例中发生70例(32%),校正HR 0·70(95% CI 0·48-1·00),非劣效性成立。
  • 符合方案分析校正HR为0·69(95% CI 0·48-1·00),非劣效性成立。
  • mITT分析中,药物相关不良事件(≥2级)在整合酶抑制剂组220例中发生16例(7%),含增效蛋白酶抑制剂组222例中发生32例(14%),p=0·043。
  • 严重不良事件或导致研究终止的不良事件两组无差异;研究期间共12例死亡(整合酶抑制剂组9例、含增效蛋白酶抑制剂组3例),与研究药物无关。

关键数值与推荐

  • 非劣效界值:主要复合终点HR的95% CI上限小于1·606,对应复合终点累积概率12%的差异。
  • mITT主要复合终点:整合酶抑制剂组22% vs 含增效蛋白酶抑制剂组32%,校正HR 0·70(95% CI 0·48-1·00)。
  • 药物相关不良事件(≥2级):7% vs 14%(p=0·043)。

临床怎么用

  • 晚期HIV疾病治疗初治成人可优先考虑比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺作为一线方案。
  • 该人群基线CD4中位41 cells/μL,整合酶抑制剂方案在病毒学与临床复合终点上不劣于含增效蛋白酶抑制剂方案且耐受性更好。

局限性

  • 开放标签设计。
  • 随访48周,为较短期结果。
  • 研究对象为欧洲7国治疗初治成人,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, clinical trials have been underpowered to assess which antiretrovirals perform best in people with advanced HIV disease. We aimed to investigate the efficacy and safety of an integrase inhibitor-containing versus a boosted protease inhibitor-containing regimen for this population. METHODS: In this open-label, multicentre, non-inferiority trial in seven European countries (Spain, France, Italy, Germany, Belgium, Ireland, and the UK), therapy-naive adults with advanced HIV disease were randomly allocated (1:1) to receive either bictegravir, emtricitabine, and tenofovir alafenamide (integrase inhibitor group) or darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (boosted protease inhibitor group) for 48 weeks. Randomisation was computer generated in permuted blocks within strata with block sizes of four and stratified by country and baseline CD4 cell count. The primary composite outcome (time to first occurrence of specified virological or clinical events) and its components were evaluated by Kaplan-Meier and Cox regression analyses in both modified intention-to-treat (mITT) and per-protocol populations. The mITT population included all randomly allocated participants who received at least one dose of the study drug, whereas the per-protocol population excluded those who received incorrect treatment. Non-inferiority of the integrase inhibitor-based regimen versus the boosted protease inhibitor-containing regimen was declared if the upper limit of the 95% CI of the hazard ratio (HR) for the primary composite endpoint was less than 1·606, corresponding to a 12% difference in the cumulative probability of the composite primary endpoint. Adverse events, a secondary endpoint, were recorded at eight visits in all participants. This trial is registered with ClinicalTrials.gov, NCT03696160, and is completed. FINDINGS: Between May 13, 2019, and June 26, 2023, 222 people were randomly assigned to the integrase inhibitor group and 225 to the boosted protease inhibitor group. Of these 447 recruited participants, 442 (99%) participants with a median CD4 count of 41 cells per μL (IQR 17-79) received at least one dose. 358 (81%) of the 442 treated participants self-reported as male and 84 (19%) female, and 276 (62%) were of White ethnicity, 83 (19%) Black, and 83 (19%) other. In the mITT analysis, the 48-week composite primary outcome event occurred in 49 (22%) of 220 participants in the integrase inhibitor group versus 70 (32%) of 222 participants in the boosted protease inhibitor group (adjusted HR 0·70 [95% CI 0·48-1·00]; non-inferiority shown). The per-protocol analysis gave a similar estimated adjusted HR of 0·69 (0·48-1·00; non-inferiority shown). By mITT, drug-related adverse events (grade ≥2) occurred in 16 (7%) of 220 participants in the integrase inhibitor group versus 32 (14%) of 222 in the boosted protease inhibitor group (p=0·043). The rates of serious adverse events or adverse events leading to study discontinuation did not differ between groups. 12 deaths occurred during the study (nine in the integrase inhibitor group and three in the boosted protease inhibitor group), not related to the study drugs. INTERPRETATION: In people with advanced HIV disease, bictegravir, emtricitabine, and tenofovir alafenamide was shown to be non-inferior to darunavir, cobicistat, emtricitabine, and tenofovir alafenamide and resulted in fewer adverse events, supporting its use as a preferred first-line antiretroviral regimen in this vulnerable population. FUNDING: Gilead Sciences and Janssen Pharmaceuticals.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Behrens GMN, Assoumou L, Liegeon G, et al. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2025. PMID: 41344354. doi:10.1016/S1473-3099(25)00681-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。